Skip to content
Resolve Therapeutics, LLC.
Resolve Therapeutics, LLC.Resolve Therapeutics, LLC.
  • About Us
    • Our Company
    • Management Team
    • SAB
    • Contact Us
  • Pipeline
    • Our Pipeline
  • Science
  • Sjögren’s Clinical Trial
  • Publications
  • News

Follow us on:

Linkedin page opens in new windowFacebook page opens in new window
  • About Us
    • Our Company
    • Management Team
    • SAB
    • Contact Us
  • Pipeline
    • Our Pipeline
  • Science
  • Sjögren’s Clinical Trial
  • Publications
  • News

Daily Archives: February 12, 2024

Resolve Therapeutics Announces Publication of Lupus Clinical Trial Results

NewsBy Development TeamFebruary 12, 2024

Miami, FL – February 12, 2024 – Resolve Therapeutics, a mid-stage clinical development biotechnology company pioneering first-in-class therapies for autoimmune diseases, today announced the publication of results from its phase 2a clinical trial of RSLV-132 in patients with Systemic Lupus Erythematosus (SLE) in Lupus Science & Medicine.

© 2020 Resolve Therapeutics. All rights reserved.

Sitemap   Terms of Use   Privacy Policy  

Go to Top